Scientific work, international teams and a concrete benefit for patients - this is what Dr. Evelyn Stuwe likes about her work as HTA Manager at Roche. In the interview, she also reveals why there are very good career opportunities in her profession.
What are your responsibilities at Roche in the area of "Market Access"?
In Germany, every new drug that comes onto the market undergoes a so-called benefit assessment. The procedure is divided into two steps: in the first part, an independent institute called IQWIG evaluates the drug and the Federal Joint Committee (G-BA) then awards a benefit assessment. In the second step, based on the G-BA's assessment, the price is negotiated with the umbrella organisation of the statutory health insurance funds. Once a drug has been approved, it will be available to patients in Germany. Pricing is free in the first year; from the second year onwards, the price that the company has negotiated with the health insurance funds applies.
As HTA Manager, I am responsible for compiling a dossier in which I use the medical data to demonstrate the additional benefit of the drug well and convincingly. I use data from clinical trials, for example. I am currently working on a lung cancer drug. It takes about a year and a half to prepare a dossier like this.